

Anna Gillio-Tos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/743269/publications.pdf>

Version: 2024-02-01

42
papers

2,700
citations

331670

21
h-index

265206

42
g-index

42
all docs

42
docs citations

42
times ranked

2875
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of HPV E6/E7 mRNA assay as primary screening test: Results from the NTCC2 trial. <i>International Journal of Cancer</i> , 2022, 151, 1047-1058.	5.1	21
2	p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. <i>Journal of the National Cancer Institute</i> , 2021, 113, 292-300.	6.3	41
3	Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. <i>International Journal of Cancer</i> , 2020, 147, 1864-1873.	5.1	16
4	Differentially methylated DNA regions in early childhood wheezing: An epigenome-wide study using saliva. <i>Pediatric Allergy and Immunology</i> , 2019, 30, 305-314.	2.6	19
5	Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. <i>International Journal of Cancer</i> , 2018, 143, 333-342.	5.1	16
6	Methylation in host and viral genes as marker of aggressiveness in cervical lesions: Analysis in 543 unscreened women. <i>Gynecologic Oncology</i> , 2018, 151, 319-326.	1.4	11
7	Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing. <i>PLoS ONE</i> , 2018, 13, e0194619.	2.5	7
8	Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1056-1065.	3.9	10
9	LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality. <i>Epigenetics</i> , 2017, 12, 11-18.	2.7	13
10	Global Hypomethylation (LINE-1) and Gene-Specific Hypermethylation (GSTP1) on Initial Negative Prostate Biopsy as Markers of Prostate Cancer on a Rebiopsy. <i>Clinical Cancer Research</i> , 2016, 22, 984-992.	7.0	22
11	Performance of Different Analytical Software Packages in Quantification of DNA Methylation by Pyrosequencing. <i>PLoS ONE</i> , 2016, 11, e0150483.	2.5	3
12	Subfertility and Risk of Testicular Cancer in the EPSAM Case-Control Study. <i>PLoS ONE</i> , 2016, 11, e0169174.	2.5	9
13	Interpretation of p16 ^{INK4a} /Ki67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. <i>Cancer Cytopathology</i> , 2015, 123, 212-218.	2.4	35
14	The Age Distribution of Type-Specific High-Risk Human Papillomavirus Incidence in Two Population-Based Screening Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 111-118.	2.5	11
15	MGMT promoter methylation in plasma of glioma patients receiving temozolomide. <i>Journal of Neuro-Oncology</i> , 2014, 117, 347-357.	2.9	43
16	Lifetime growth and risk of testicular cancer. <i>International Journal of Cancer</i> , 2014, 135, 695-701.	5.1	16
17	Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. <i>Journal of Clinical Virology</i> , 2014, 60, 257-263.	3.1	25
18	Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. <i>BMC Infectious Diseases</i> , 2013, 13, 238.	2.9	19

#	ARTICLE	IF	CITATIONS
19	Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 168-176.	10.7	139
20	A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years. <i>BMC Infectious Diseases</i> , 2013, 13, 74.	2.9	20
21	Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2901-2907.	3.9	26
22	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. <i>PLoS ONE</i> , 2013, 8, e81171.	2.5	21
23	Methylation of APC and GSTP1 in Non-Neoplastic Tissue Adjacent to Prostate Tumour and Mortality from Prostate Cancer. <i>PLoS ONE</i> , 2013, 8, e68162.	2.5	35
24	HPV Testing Is an Efficient Management Choice for Women With Inadequate Liquid-Based Cytology in Cervical Cancer Screening. <i>American Journal of Clinical Pathology</i> , 2012, 138, 65-71.	0.7	11
25	DNA methyltransferase 3b (DNMT3b), tumor tissue DNA methylation, Gleason score, and prostate cancer mortality: investigating causal relationships. <i>Cancer Causes and Control</i> , 2012, 23, 1549-1555.	1.8	7
26	Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. <i>European Journal of Cancer</i> , 2012, 48, 1633-1637.	2.8	50
27	Case-control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis. <i>BMC Cancer</i> , 2012, 12, 618.	2.6	14
28	Prevalence and Follow-Up of Occult HCV Infection in an Italian Population Free of Clinically Detectable Infectious Liver Disease. <i>PLoS ONE</i> , 2012, 7, e43541.	2.5	39
29	Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin's lymphoma. <i>Cancer Epidemiology</i> , 2010, 34, 709-712.	1.9	13
30	Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2010, 11, 249-257.	10.7	797
31	Occult HCV Infection: An Unexpected Finding in a Population Unselected for Hepatic Disease. <i>PLoS ONE</i> , 2009, 4, e8128.	2.5	66
32	GP5+/6+ SYBR Green methodology for simultaneous screening and quantification of human papillomavirus. <i>Journal of Clinical Virology</i> , 2009, 45, 90-95.	3.1	20
33	Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. <i>Lancet Oncology</i> , The, 2008, 9, 937-945.	10.7	170
34	Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. <i>Journal of the National Cancer Institute</i> , 2008, 100, 492-501.	6.3	259
35	Association Between Hypermethylated Tumor and Paired Surgical Margins in Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2007, 13, 5089-5094.	7.0	63
36	Efficient DNA extraction from 25-year-old paraffin-embedded tissues: study of 365 samples. <i>Pathology</i> , 2007, 39, 345-348.	0.6	68

#	ARTICLE	IF	CITATIONS
37	HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. <i>European Journal of Cancer</i> , 2007, 43, 476-480.	2.8	65
38	Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. <i>Journal of Clinical Virology</i> , 2007, 38, 7-13.	3.1	33
39	Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. <i>Cancer</i> , 2007, 110, 1745-1751.	4.1	59
40	Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2006, 98, 765-774.	6.3	275
41	Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. <i>Journal of Clinical Virology</i> , 2006, 36, 126-132.	3.1	19
42	Prevalence of human papillomavirus infection in women in Turin, Italy. <i>European Journal of Cancer</i> , 2005, 41, 297-305.	2.8	94